Consent pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the quality, efficacy, and safety of therapeutic goods, including medicines, medical devices, and blood products. This Act was established to address the need for a comprehensive legal framework governing the importation, supply, and control of therapeutic goods within Australia, thereby ensuring public health and safety. In particular, the Therapeutic Goods Act 1989 was designed to fill the gap in regulatory oversight for therapeutic goods that were previously inadequately managed under existing legislation. The policy objective of the Act is to facilitate the regulation of therapeutic goods in a manner that balances the need to protect public health while also encouraging innovation and access to necessary therapeutic products. In the specific case of the Therapeutic Goods Act 1989, sections 14 and 14A allow for the granting of consent to import and supply therapeutic goods that do not strictly comply with certain regulatory requirements, such as labelling. This is evident in the consent granted for the importation and supply of fidaxomicin (DIFICID) 200 mg tablets, where non-compliance with specific labelling requirements was allowed under certain conditions, ensuring that the necessary information was still made available to healthcare professionals through alternative means.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, blood and tissues, and cosmetics. This legislation primarily governs entities involved in the supply of these goods, including manufacturers, importers, sponsors, and suppliers, ensuring that they comply with quality, safety, and efficacy standards. The Act’s jurisdictional reach extends across the Commonwealth, with the Therapeutic Goods Administration (TGA) acting as the regulatory body under the Department of Health. Notably, the Act allows for the import and supply of therapeutic goods that do not fully conform to certain regulatory standards under specific conditions, as illustrated in the case of fidaxomicin (DIFICID) 200 mg tablets, where the TGA granted consent for Canadian labelling to be used with additional over-stickers providing necessary information. The application of this consent is limited to a specific batch and conditions that ensure the safety and proper information dissemination to healthcare professionals. The Act’s provisions can be further defined and extended through subordinate instruments, which may impose additional requirements or clarifications on the primary legislation.

Key Provisions

The Therapeutic Goods Act 1989, particularly sections 14 and 14A, allows for the consent of the Secretary of the Department of Health to import and supply therapeutic goods that do not fully conform to the Australian labelling requirements, under certain conditions. In this instance, Merck Sharp & Dohme Australia Pty Ltd applied for and was granted consent to import and supply fidaxomicin (DIFICID) 200 mg tablets in bottles that do not meet the specific labelling requirements outlined in the Therapeutic Goods Order No. 69. This consent is a temporary measure, effective from 7 July 2015 until the supply of the specified batch of 300 units is exhausted. The obligations imposed on Merck Sharp & Dohme Australia Pty Ltd under this consent include using Canadian labels for the bottles, which are accompanied by over-stickers that provide the necessary warning statements, Australian storage conditions, and the name and address of the Australian sponsor or supplier of the product and ARTG number. Additionally, a ‘Dear Healthcare Professional’ letter, identical to the one provided to the Therapeutic Goods Administration (TGA) on 1 July 2015, must be supplied with the Canadian stock. This letter instructs healthcare professionals to disregard the Canadian labelling information on the bottle and refer to the over-labelling on the carton. These measures ensure that critical information is still communicated to healthcare professionals, despite the non-compliance with certain labelling requirements. Failure to adhere to the conditions of this consent may result in legal consequences. Under the Therapeutic Goods Act 1989, supplying therapeutic goods that do not meet the prescribed standards can lead to enforcement actions by the TGA. Such actions may include fines, product recalls, or other regulatory measures to ensure public safety and compliance with the Act. The specific penalties for breaches are determined by the nature and severity of the breach, but can include substantial financial penalties and, in severe cases, criminal charges. It is imperative for Merck Sharp & Dohme Australia Pty Ltd to comply strictly with the conditions of the consent to avoid these potential consequences.